Plutux
$18.45
+0.14%
2026-09-04 12:38:00 EDT+$0.03
Technology
Software - Application
NASDAQ
Active Trading

Simulations Plus, Inc. (SLP) is a worldwide developer of sophisticated software and services aimed at enhancing drug discovery and development processes. The ...

Price Action

$18.45
+0.14%+$0.03
High
Low
52W High-12.2%
Rel. vol
Interval
Range2.8h
VolumeSMA5SMA10
Simulations Plus, Inc. (NASDAQ: SLP) is a worldwide developer of sophisticated software and services aimed at enhancing drug discovery and development processes. The company employs artificial intelligence and machine learning technologies to create tools for modeling, simulation, and predicting molecular characteristics. Its operations are divided into four main business units: ...Simulations Plus, Inc. (NASDAQ: SLP) is a worldwide developer of sophisticated software and services aimed at enhancing drug discovery and development processes. The company employs artificial intelligence and machine learning technologies to create tools for modeling, simulation, and predicting molecular characteristics. Its operations are divided into four main business units: Simulations Plus, Cognigen, DILIsym, and Lixoft. Among its diverse software offerings are GastroPlus, which models the absorption and drug interactions of compounds in both human and animal subjects, as well as DDDPlus and MembranePlus for various simulations. The company also provides a range of products built on mechanistic and mathematical models, such as its quantitative systems pharmacology software like DILIsym, NAFLDsym, IPFsym, RENAsym, and MITOsym. Furthermore, Simulations Plus offers the ADMET Predictor, a chemistry-focused computer program that forecasts molecular properties from structural inputs, alongside MedChem Designer, MonolixSuite, and PKPlus for additional modeling and simulation needs. Beyond software, the company extends its expertise through various services, including contract research for population modeling and simulation, specialized training and consultation to advance pharmacometrics studies, and clinical-pharmacology consulting to aid in regulatory submissions. Simulations Plus serves a broad spectrum of clients globally, including pharmaceutical, biotechnology, agrochemical, cosmetic, and food companies, as well as academic institutions and regulatory bodies. The company was founded in 1996 by Walter Woltosz and maintains its headquarters in Research Triangle Park, North Carolina, though it was originally incorporated in Lancaster, California. As of the latest data, the company employs 212 full-time employees. Financially, Simulations Plus has shown a gross profit margin of 63.4%, an operating margin of 14%, and a net profit margin of 9.9% over the trailing twelve months. Its market capitalization stands at approximately $370.5 million, with a price-to-earnings ratio of 44.7. The company's commitment to innovation is reflected in its research and development expenditure, which accounts for 14.1% of revenue. Under the leadership of CEO Shawn O'Connor, Simulations Plus continues to advance agentic drug development, aiming to accelerate the journey from discovery to clinical success by integrating AI and mechanistic modeling. The company's vision is to be the global leader in model-informed and AI-accelerated drug development, creating value for clients by optimizing drug development programs and improving patient outcomes. With a strong balance sheet, minimal debt, and a focus on high-value software solutions, Simulations Plus is well-positioned to capitalize on the growing demand for biosimulation in the pharmaceutical industry.
Founded
1996
Employees
213
CEO
Shawn O'Connor
Full Name
Simulations Plus, Inc.
Sector
Technology
Industry
Software - Application
ROE
6.18%
Market Cap
$0.37B
Current Ratio
5.54
WACC
10.82%
ROIC
6.18%

Contact Information

661 723 7723
800 Park Offices Drive, Research Triangle Park, NC 27709

Related stocksSoftware - Application

Browse all US stocks

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

© Plutux Technology Limited 2026